Real‐world reported adverse events related to systemic immunomodulating therapy in patients with atopic dermatitis: Results from the <scp>TREAT NL</scp> (<scp>TREatment</scp> of <scp>ATopic</scp> eczema, the Netherlands) registry
Annelie H. Musters(Amsterdam University Medical Centers), Phyllis I. Spuls, Anh Ly Nguyen(Leiden University Medical Center), Florine L van Lookeren(Amsterdam UMC Location University of Amsterdam), Hilde Lapeere(Johns Hopkins University), Naomi T. Jessurun(Netherlands Pharmacovigilance Centre Lareb), Wouter Ouwerkerk(University of Amsterdam), Louise A. A. Gerbens(Amsterdam UMC Location University of Amsterdam), Lian F. van der Gang(Utrecht University), Angela L. Bosma(Amsterdam University Medical Centers), M.A. Middelkamp‐Hup(Amsterdam University Medical Centers), Sofie De Schepper(Ghent University Hospital)
Cited by 14
Related Papers
Definition of treatment goals for moderate to severe psoriasis: a European consensus
|Archives of Dermatological Research|2010|892
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
|Journal of Clinical Oncology|2015|619
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
|Journal of the European Academy of Dermatology and Venereology|2022|419
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
|Journal of Investigative Dermatology|2016|377